About
About Interdict Bio
Interdict Bio develops small molecule inhibitors called Interdictors™ that inhibit protein synthesis by the ribosome in a context-dependent manner. The word ‘interdict’ means to intercept, cut off, or destroy firepower to stop or hamper an enemy. Interdictors™ prevent disease-causing proteins from being synthesized before they even have a chance to enter the cell and cause harm.
Together, our scientific team, advisors, founders and investors are committed to advance the novel Interdictor™ modality and provide breakthrough treatments for patients with high, unmet medical need in oncology and neurodegenerative diseases.
Team
Larry Hamann, Ph.D.
Co-founder, President & CEO
Cassandra Choe-Juliak, M.D.
CMO
Margaux Bennett, Ph.D.
CBO
Michael Geremia, M.B.A.
CFO
Sami Bahmanyar, Ph.D.
VP
Computational Sciences
Anthony Schuller, Ph.D.
Director
Head of Biology
Zef Könst, Ph.D.
Director
Drug Discovery
Paul Sauer, Ph.D.
Principal Investigator
Structural Biology
Mikael Holm, Ph.D.
Principal Investigator
Biochemistry
Paige Diamond, Ph.D.
Senior Investigator
Genomics
Lucas Ferguson, Ph.D.
Senior Investigator
Genomics
Margot Meyers, Ph.D.
Investigator
Chemical Biology
Timothy Lehmberg, B.A.
Investigator
Cell Biology
Grant Wienker, B.S.
Research Associate
Cell Biology
Hailey Adams, B.A.
Research Associate
Structural Biology
Scientific Advisors
Danica Fujimori, Ph.D.
Co-founder
UCSF
James Fraser, Ph.D.
Co-founder
UCSF
Alan Ashworth, Ph.D., F.R.S.
Scientific advisor
UCSF
Pamela Munster, M.D.
Scientific advisor
UCSF
Donald McDonnell, Ph.D.
Scientific advisor
Duke University
Dean Felsher, M.D., Ph.D.
Scientific advisor
Stanford University
Tom Rovis, Ph.D.
Scientific advisor
Columbia University
Board of directors
Mariana Mihalusova, Ph.D.
Board Director
Venrock
Bryan Roberts, Ph.D.
Board Observer
Venrock
Dave Maki, J.D.
Board Director
Altitude Life Science Ventures
Robert Blazej, Ph.D.
Board Observer
Mission Bay Capital
Larry Hamann, Ph.D.
Board Director
Interdict
Investors
